Drug maker Proteome Sciences has completed the in-vivo study of its CK1D inhibitor programme in Alzheimer's disease on time, with the results showing that both of the lead compounds for CK1D demonstrated improved cognitive function.
The firm said the results provide important in-vivo proof of principle and demonstrate the efficacy of its compounds.
The next phase, which will start immediately in January, is to undertake and complete a comprehensive assessment of biological indicators and drug levels in various tissues.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Christopher Pearce, Chief Executive Officer, said: "Our goal was to deliver in-vivo proof of principle for CK1D in Alzheimer's disease. We are delighted that this has been successfully achieved in 2012.
"These results are most timely as major pharmaceutical companies and academia have increasingly been switching attention to the importance of tau tangles in combination with amyloid aggregation in Alzheimer's.
"In light of UK government's recent commitment to fully fund NHS access to novel treatments for AD, we believe there is significant potential for CK1D inhibitors to positively affect the lives of sufferers and their carers. We will continue to push our CK1D programme forward and will actively engage with the pharmaceutical industry to bring our compounds to clinical trials as soon as possible".
The share price rose 1.19% to 64p by 11:00.
NR
